Since both RT and CDK4/6 inhibitors elicit cellular senescence as part of their in vivo effects [36–41], we hypothesized that the differential efficacy of RT followed by (→) P vs P→RT could depend on the differential accumulation of senescent cells in the tumor microenvironment (TME). This evidence concerns the gene CDK4 and neoplasm.